Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1/PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of varenicline 2.0 mg/day treatment for 2 weeks with smoking test done in laboratory on Day 8 and a 1 week quit attempt from Day 8-14.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking

NCT00594204

Smoking Cessation

COMPLETED PHASE4

A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider

NCT01244061

Smoking Cessation

COMPLETED PHASE4

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

NCT00747643

Tobacco Dependence

COMPLETED NA

Measuring Smoking Behaviors While Using Varenicline

NCT00948155

Nicotine Dependence

COMPLETED PHASE4

Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use

NCT00717093

Tobacco Use Cessation

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nicotine Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Varenicline

Group Type ACTIVE_COMPARATOR

varencline

Intervention Type DRUG

2.0 mg/day varencline (1.0 mg BID)

2

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

matching placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

varencline

2.0 mg/day varencline (1.0 mg BID)

Intervention Type DRUG

placebo

matching placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chantix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 10 cigarettes/day
* Interest in quitting smoking
* Willgness to comply with overnight smoking abbstiennce period followed by lab smoking test

Exclusion Criteria

* Pregnancy
* Axis I psychiatric disorder which require treatment with psychoactive medication and would make study compliance difficult.
* Clinically significant medical condition in opinion of study clinician
* Drug or alcohol dependence inlast 12 months
* Use of other smoking cessation medications ot treatment progams in last 2 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No